Radiopharm Theranostics将Radiopharm Ventures的持股比例从75%提高至87.5%，B7 H3候选人Betabart有望在2026年第一季度实现首例患者给药

2026-01-12 20:07

Radiopharm Ventures, LLC, is a joint venture created in 2022 between MD Anderson Cancer Center and Radiopharm Theranostics
Leading candidate Betabart, a monoclonal antibody targeting B7H3, has received FDA IND clearance for a Phase I therapeutic trial in multiple solid tumors expected to dose the first patient in Q1 2026
First clinical trial globally targeting B7H3 with a systemic radiopharmaceutical
Two additional preclinical Radiopharm Ventures' assets show early positive results with plans to move to final candidate selection in 2026